India Pharma Outlook Team | Friday, 13 June 2025
An International Leader in Pharmaceutical Excipients Kolkata, 13 June 2025: The biggest manufacturer of microcrystalline cellulose (MCC) in India, Sigachi Industries Ltd., is steadily raising the bar for pharmaceutical excipients worldwide while pursuing a strategic expansion into specialty chemicals and active pharmaceutical ingredients (APIs). Sigachi is currently thriving as a vertically integrated pharmaceutical company thanks to strong financial growth, a broad portfolio, and an increasing global presence.
In FY25, the firm reported a 25.42% increase in sales to ?5,003 million and a 46.21% increase in EBITDA, driven by strategic collaborations across 65 countries, API capacity expansions, and excipient demand. For the same time period, the company's EBITDA margin was 22.38%, while its PAT was 14.09%. This year builds on Sigachi's stellar five-year performance, which has seen the company increase core revenues, generate a 28% PAT CAGR, keep debt low, and maintain excellent operating margins.
Also Read : API Prices Plunge, Easing Costs for Indian Pharma Manufacturers
“FY25 has been a transformative year for Sigachi,” said Mr. Amit Raj Sinha, MD & CEO of Sigachi Industries. “We’ve built on our core strengths in excipients, while laying a strong foundation for future-ready API and specialty chemical capabilities. Our upcoming Orvakal facility marks the beginning of a new chapter in vertical integration, scalability, and regulatory alignment. It will anchor our next phase of growth and enhance our responsiveness to evolving global customer requirements” Strategic API Push: New Facility at Orvakal, Andhra Pradesh Sigachi has received Terms of Reference (ToR) approval from the State Environment Impact Assessment Authority (SEIAA), Andhra Pradesh, for a cutting-edge Bulk Drugs and Specialty Chemicals facility in Orvakal, Kurnool District.
, CDSCO.jpg)
